- BriaCell Therapeutics (TSX:BCT) is reporting that the first metastatic breast cancer patient treated with its Bria-OTS candidate is now cancer-free in the lungs
- Bria-OTS is a personalized off-the-shelf cancer immunotherapy
- BriaCell is a clinical-stage biotechnology stock developing immunotherapies to transform cancer care
- BriaCell stock is up by 27.52 per cent trading at C$9.22 per share as of 9:41 am ET, but remains down by 88.31 per cent year-over-year
BriaCell Therapeutics (TSX:BCT), a biotech stock developing cancer immunotherapies, is reporting that the first metastatic breast cancer (MBC) patient treated with its Bria-OTS candidate is now cancer-free in the lungs.
After only four doses over a two-month period, Bria-OTS successfully resolved a 78-year-old woman’s lung metastasis stemming from a breast cancer tumor with no related toxicity, while keeping additional bone and lymph node metastases in stable condition.
Participants in the phase-1/2a study must have metastatic breast cancer and at least two failed prior therapeutic interventions, such as chemotherapy. The study is evaluating the safety and efficacy of Bria-OTS as monotherapy and in combination with an immune checkpoint inhibitor.
Bria-OTS is a personalized off-the-shelf immunotherapy derived from BriaCell’s lead candidate, Bria-IMT, which is currently in a phase-3 study for metastatic breast cancer.
Leadership insights
“Despite recent advancements in cancer treatment with antibody-drug-conjugates (ADCs) and immune check point inhibitors (CPIs), metastatic breast cancer remains an unmet medical need as many patients do not respond to these treatments,” Neal Chawla, associate director of clinical research at the Sarcoma Oncology Center and principal investigator for the Bria-OTS study, said in a statement. “We are very impressed by the clinical response observed showing rapid and robust clinical activity in addition to excellent tolerability in the first patient treated with Bria-OTS and look forward to reproducing these results in other cancer patients in the study.”
“This data supports our hypothesis of personalized immunotherapy with Bria-OTS, potentially leading to new and effective treatment of metastatic breast cancer,” commented William V. Williams, BriaCell’s president and chief executive officer. “We hope to transform the way we treat cancer patients with our novel personalized off-the-shelf immunotherapy approach.”
“Resolution of metastatic lung disease in this breast cancer patient highlights the clinical effectiveness of Bria-OTS and its therapeutic potential in MBC,” added Giuseppe Del Priore, BriaCell’s chief medical officer. “This result represents a major step towards advancing our innovative technology platform and our goal of offering safe and effective treatment to MBC patients and our plans to extend into prostate cancer, melanoma and lung cancer.”
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology stock developing immunotherapies to transform cancer care.
BriaCell stock (TSX:BCT) is up by 27.52 per cent trading at C$9.22 per share as of 9:41 am ET. The stock has given back 88.31 per cent year-over-year.
Join the discussion: Find out what everybody’s saying about this cancer-focused biotech stock on the BriaCell Therapeutics Corp. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo of a lung scan before and after BriaCell Therapeutics’ Bria-OTS cancer treatment: BriaCell Therapeutics)